Article Abstract

Claus-Henning Koehne: the awareness of K-Ras is a great progress in molecular targeted therapy

Authors: Nancy Q. Zhong


Dr. Claus-Henning Koehne (Figure 1), Chairman of the Department of Hematology and Oncology, Klinikum Oldenburg, Germany, is an outstanding oncologist and hematologist with about 80 publications in less than two decades. In 2012 Chinese Society of Clinical Oncology (CSCO) conference, he gave a lecture on “Clinical practice of biological and molecular target agents”. After his lecture, Dr. Koehne was interview by Editor of Chinese Clinical Oncology (CCO) and gave us a brief introduction of the achievement and limitation in molecular targeted chemotherapy, and the clinical features of aggressive disease in China and Germany.